rheumatology and internal medicine associates :: Article CreatorDivision Of Rheumatology
The Saint Louis University Division of Rheumatology specializes in the care of both adults and children with rheumatic diseases with an emphasis on rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and other connective tissue diseases (CTD). SLU's division is consistently ranked in the top 25 of rheumatology fellowship training programs.
Program Overview
The division is one of the most well-known clinical rheumatology divisions in the Midwest, seeing more than 7,500 patients per year. We are also the eighth-largest pediatric rheumatology clinic in the country. The division of rheumatology has both outstanding educational and research potential. The division holds an R01 research grant from the National Institutes of Health (NIH) for five years for studies in systemic lupus complexes and on immune regulatory T-cells headed by Anil Chauhan, M.D. We continue to have other basic projects in pediatric and adult rheumatology, as well as many transition projects in rheumatology being performed by our faculty.
We offer the largest rheumatology clinics in the Midwest for children and adolescents and the largest adult clinic in Missouri. The division also includes a rheumatology laboratory that offers a wide variety of immunological testing.
Faculty Publications
Moore TL: Juvenile idiopathic arthritis. In: "Conn's Current Therapy 2009", (eds) RE Rakel, ET Bope, pp 983-986, 2009 Low JM, Chauhan AK, Gibson DS, Zhu M, Chen S, Rooney ME, Ombrello MJ, Moore TL: Proteomic analysis of circulating immune complexes in juvenile idiopathic arthritis reveals disease associated proteins. Proteomics Clin App 3: 829-840, 2009 Reed MR, Gilliam BE, Syed RH, Moore TL: Rheumatic manifestation of Parvovirus B19 in children. J Pediatr Infect Dis 4: 321-331, 2009 Gilliam BE, Reed MR, Syed RH, Moore TL: Rheumatic manifestation of Epstein-Barr virus in children. J Pediatr Infect Dis 4: 333-342, 2009 Moore TL: Juvenile idiopathic arthritis. In "Conn's Current Therapy 2010," (eds) RE Rakel, ET Bope, Kellerman R, pp 987-989, 2010 Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL: Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol 9: 8: 1-16, 2011 Moore TL: Pathogenesis and diagnosis of viral arthritis: Update. Up to Date Rheumatol 19: 1-10, 2011-2014 Moore TL, Syed RH: Specific viruses that cause arthritis: Update. Up to Date Rheumatol 19: 1-18, 2011-2014 Chauhan AK, Moore TL: T-cell activation by the terminal complex of complement and immune complexes. J Biol Chem 287: 38627-38637, 2011 Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL: Significance of complement components Clq and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: Support for classical complement pathway activation. Clin Exp Rheumatol 29: 1049-1056, 2011 Chauhan AK, Moore TL: Immune complexes and late complement proteins trigger activation of Syk tyrosine kinase in human CD4+ T cells. Clin Exp Immunol 167: 235-245, 2012 Gilliam BE, Ombrello AK, Burlingame R, Pepmueller PH, Moore TL; Measurement of autoantibodies in pediatric and adolescent-onset systemic lupus erythematosus and their significant relationship with disease-associated manifestations. Semin Arthritis Rheum 41: 840-848, 2012 Moore TL: Diseases of the joints. In Pathy's "Principles and Practice of Geriatric Medicine", eds JE Morley, AJ Sinclair, B Velles (5th Edition), pp 1145-1152, 2012 Gilliam BE, Moore TL: The role of anti-cyclic citrullinated peptide (CCP) antibodies in early detection of rheumatoid arthritis: an overview of the INOVA Diagnostics, Inc. QUANTA lite CCP Assays. Expert Opin Med Diagn 10: 359-369, 2012 (PMed 23480744) Gibson DS, Newell K, Evans AN, Finnegan S, Manning G, Scaife C, McAllister C, Pennington SR, Duncan MW, Moore TL, Rooney ME: Vitamin D binding protein isoforms as candidate predictors of disease extension in childhood arthritis. J Proteomics 10:1016-1029, 2012 (PMed 22771520) Gilliam BE, Chauhan AK, Moore TL: Evaluation of anti-cyclic citrullinated type II collagen and anti-cyclic citrullinated vimentin autoantibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol 11: 31:1-10, 2013 (PMed 23987731) Syed R, Moore TL: Juvenile idiopathic arthritis: pathogenesis, presentation, and treatment, In "Encyclopedia of Medical Immunology", eds G Tsokos, IR Mackay, NR Rose, in press, 2013 Moore TL, Gilliam BE, Crespo-Pagnussats, Feller L, Chauhan AK: Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated ?-enolase antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 32: in press, 2014. Chauhan AK, Chen C, Moore TL, DiPaolo RJ: Induced expression of Fc?RIIIa (CD16a) (CD/Ga) on CD4+ T cells triggers generation of IFN? High subset. J Biol Chem 290, in press, 2015. Dalrymple AM, Moore TL: Laboratory evaluation in pediatric autoimmune disease. Ped Rev, in press, 2015. Research Grants Research Lab Priority Projects
Studies on systemic Lupus on Regulatory T-cells Studies in Systemic Lupus on Interferon Signatures Studies in Systemic Lupus on Syk and Immune Complexes Studies in Juvenile Idiopathic Arthritis on Isotypes of Anti-CCP Antibodies and Rheumatoid Factors and Glycosylation Current Studies BENLYSTA™ Study
5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without BENLYSTA™ (Belimumab)
Principal Investigator: Reema Syed, MD
Terry L. Moore, M.D.DirectorProfessor of Internal Medicine, Pediatrics, Molecular Microbiology and Immunology Rama Atluri, M.D.Professor of Internal Medicine
Adam Kilian, M.D.Director, Rheumatology Fellowship ProgramAssistant Professor, Division of Rheumatology
Muhammad Zaheer, M.D.Assistant Professor of Internal Medicine
Alice Gottlieb MD, PhD
Alice Bendix Gottlieb MD, PhD, Medical Director and Clinical Professor, Mount Sinai Beth Israel Dermatology, Kimberly and Eric J. Waldman Department of Dermatology at The Icahn School of Medicine at Mount Sinai, is a superb physician who has made a significant mark in the scientific field of Dermatology and Rheumatology.
After graduating from Brandeis University Summa Cum Laude with Honors in Chemistry, Dr. Gottlieb entered the combined MD-PhD program at The Rockefeller University-Cornell University Medical College where she was one of the first females to be admitted into the program. She received her PhD from the Rockefeller Unversity in 1979 followed by her MD at Cornell University Medical Center in 1980. Dr. Gottlieb entered The New York Hospital for her internal medicine residency, which she completed in 1982, followed by a rheumatology fellowship at the Hospital for Special Surgery completed in 1984 and returned to the New York Hospital for her dermatology residency which she completed in 1993. Dr. Gottlieb founded the Tufts Dermatology residency program (which formally was shared with Boston University) and served as Chair of Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She also founded the Dermatology Division at UMDNJ-Robert Wood Johnson Medical School where she served as Professor of Medicine, Director of the Clinical Research Center and Founding Director of the Psoriasis Center of Excellence. Before joining the Mt Sinai faculty she was a Professor of Dermatology at New York Medical College in New York City.
Dr. Gottlieb is an internationally recognized expert in the field of psoriasis and psoriatic arthritis. Her research uses targeted immunobiologics as pathogenic probes, providing new understanding of the pathogenesis of psoriasis and providing the foundation for biologic drug development in these two debilitating diseases. Through a study she had published in Lancet in 2001, Dr. Gottlieb was the first to show the efficacy of TNF blockers as monotherapy for moderate to severe psoriasis. Her research led to multiple TNF blockers being FDA-approved for psoriasis which revolutionized the care of psoriasis and psoriatic arthritis patients. In addition, Dr. Gottlieb was one of the first scientists to demonstrate that psoriasis is a T cell mediated disease. She showed that treatment with a T cell-specific immunotoxin cleared psoriasis clinically and histologically. With her published studies and public presentations she has been able to convince pharmaceutical companies to use psoriasis as their proof-of-concept disease when testing new immunomodulators that may decrease T cell and dendritic cell cytokine production. So far, her research has affected drug development in psoriasis, psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and transplantation.
Through her research, Dr. Gottlieb has authored over 462 peer-reviewed articles making appearances in journals, such as the Lancet, the Journal of Experimental Medicine, Journal of Investigative Dermatology, Archives of Dermatology, the Journal of the American Academy of Dermatology, the New England Journal of Medicine. Additionally, she has presented her research at more than 320 dermatology and rheumatology conferences in Asia, Europe and the United States, as well as the FDA and the National Academy of Sciences. In 2001, she was the recipient of the American Skin Association's Psoriasis Research Achievement Award in recognition of her "important contributions to the scientific understanding of psoriasis." In a survey of top psoriasis experts from around the world, Dr. Gottlieb came in first place with 1506 first author citations. She continues her innovative clinical research at Mount Sinai.
In addition, she is a noteworthy researcher, but she is also an exceptionally outstanding clinician and educator. She is triple boarded in dermatology, rheumatology and internal medicine, making her one of only a handful of doctors in the United States to be certified in all three specialties. Her research has helped the numerous students, residents and fellows she has trained, as well as the dermatologic community at large, who want to understand how to diagnose and manage psoriatic arthritis. She is an excellent teacher which is why it is no surprise she has won the Excellence in Teaching Award from the Department of Dermatology at Tufts University Medical School/Tufts Medical Center. In 2016, she received the National Psoriasis Foundation Outstanding Educator in Psoriatic Disease Award. In 2018, she was honored with an award from the National Psoriasis Foundation for her leadership in psoriasis and psoriatic arthritis research and care.
Dr. Gottlieb is the recipient of numerous awards including Excellence in Teaching Award from the Departments of Dermatology at both the Icahn School of Medicine at Mount Sinai and Tufts University Medical School/Tufts Medical Center, Honorary Membership in Alpha Omega Alpha in recognition of medical student teaching, a Research Mentorship award from the Internal Medicine house staff and a Mentorship Award from the American Chemical Society for mentoring minority high school students in bench and clinical research. She was elected to the Board of Directors of the American Academy of Dermatology for 2011-2015. She is a member of the American Dermatologic Association and others.
Over the course of her illustrious career, she held many important leadership positions the Board of Directors for the American Academy of Dermatology and the Women's Dermatologic Society, and Chairman, Networking Committee of the Women's Dermatologic Society, as well serving as a Medical Advisory Board member and Editor in Chief of the Journal of Psoriasis and Psoriatic Arthritis, which is physicians' journal of the National Psoriasis Foundation. In 2015, she has been awarded the Honorary Membership into the American Academy of Dermatology for her exceptional leadership and service.
Dr. Gottlieb has served on the Editorial Board of the Journal of Cutaneous Medicine and Surgery and American Academy of Dermatology, the American Clinical Dermatology, Editor in Chief of the Journal of Psoriasis and Psoriatic Arthritis, and Editor of Dermatology Section of Clinical Immunology. She is also an elected member of the Noah Worcester Dermatologic Society and the Association of Professors of Dermatology.
She is the founder and President of the International Dermatology Outcome Measures (IDEOM) group. Founded in 2013, this 501c3 non-profit, consortium of patients, physicians, pharmaceutical scientists and other stakeholders is dedicated to bringing outcome measures to dermatologic clinical research and practice that satisfy the needs of all stakeholders. She is on the Executive Board of GRAPPA, the group devoted the research in psoriasis and psoriatic arthritis. She is a councilor of the International Psoriasis Council.
Dr. Gottlieb practices at the Mount Sinai Beth Israel where she puts her patients first and she continues her innovative clinical research in psoriasis, psoriatic arthritis, hidradenitis suppurativa and vitiligo and other immune mediated disorders. She continues to enjoy her mentoring and teaching of the dermatology residents, young faculty and medical students.
David John MD, Board-Certified In Rheumatology And Internal M, Rheumatology Expert, LLC
David John, M.D. Is an Assistant Professor of Medicine at the University of Missouri-Kansas City School of Medicine. He is Boarded in both Internal Medicine and Rheumatology, with expertise in rheumatologist disorders, autoimmune disease, fibromyalgia and many soft tissue musculoskeletal problems. David John has past and present experience in records review, reports and expert witness testimony.
His Rheumatology fellowship was at the University of Michigan Rackham Arthritis Unit in Ann Arbor. That was followed by a long private practice career in Honolulu before accepting a position at the University of Missouri. David John's undergraduate major was English Literature. He is, thus, articulate and adept at writing as well as skilled at grasping the "big picture" in complex medical scenarios.
Comments
Post a Comment